Navigation Links
Biomarker identified in relation to drug response in refractory urothelial cancer
Date:3/31/2012

CHICAGO The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.

"Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea Necchi, M.D., faculty member in the department of medicine at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. "Patients who fail to be cured after multiple chemotherapy regimens have a poor survival estimate, and palliative care is a reasonable trade-off."

Data from the phase II proof-of-concept trial identified pazopanib as the first targeted compound to have clinically meaningful activity in patients with refractory urothelial cancer, according to Necchi.

"Our data indicate that pazopanib seems to be a legitimate drug in this disease," said Necchi. "Most interestingly, our biomarker analysis clearly pointed out the role of rising levels of circulating interleukin-8 as an early and potentially practice-changing indicator of tumor resistance and poor survival."

The researchers assigned 41 patients with relapsing or progressing urothelial cancer between 2010 and 2011 to 800 mg once-daily pazopanib. All patients had at least one prior chemotherapy regimen for metastatic disease.

At follow-up, seven patients had a partial response to therapy and 24 patients had stable disease an overall clinical benefit of 76 percent. Median progression-free survival was 2.6 months, and median overall survival was 4.7 months. However, 10 percent of patients had a long-term cure after a median follow-up of 19 months.

The researchers examined blood samples for predictive biomarkers at baseline and every four weeks. They found that early rising levels of interleukin-8 (e.g., after four weeks of pazopanib) were associated with tumor progression and shorter overall survival.

"This trial gave a clear proof of concept that will require confirmation on a larger number of patients," Necchi said. "However, the preliminary findings, mainly regarding the role of interleukin-8 levels, have the potential to change at least the concept of new trial design with antiangiogenic agents in this disease."

Necchi served as an adviser and consultant for GlaxoSmithKline Inc. The current study was sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori. GlaxoSmithKline Inc. provided the drug supply and granted independent radiologic review, which was performed at Columbia University Medical Center.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Panel of serum biomarkers may reduce number of lung biopsies needed
2. Biomarkers identify acute kidney injury in emergency patients
3. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
4. Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
5. Mass. General Cancer Center and Vall dHebron Institute of Oncology biomarker alliance
6. Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease
7. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
8. Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio
9. FDA clears biomarker test for ovarian cancer
10. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
11. Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... With long-term experience in ... of Business Intelligence and Informatics, effective immediately. http://www.fluidedgeconsulting.com , As a ... a healthcare business and financial strategist for over 20 years. By leveraging ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Get With The Guidelines®-Stroke Gold Plus Achievement Award with Target: StrokeSM Honor ... Healthcare System, recognizes its commitment to emergency stroke care to ensure that ...
(Date:5/25/2016)... City, MO (PRWEB) , ... May 25, 2016 , ... ... collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free Sport®) ... Free Sport”. This conference, to be held July 12 – 13 in Kansas City, ...
(Date:5/25/2016)... ... May 25, 2016 , ... According to an ... of hernia mesh that would effectively fight against common bacteria and protect against surgical ... healing process from hernia repair surgery even safer and could further reduce ...
(Date:5/25/2016)... ... ... The Bank of America Charitable Foundation has awarded a grant to the General ... employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, Bank of ... Medisend, parent organization and home of the General Myers Veterans Program. , “The ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers ... her organs from the inside out.  This disease has ... dependent on her children and grandchildren to leave her ... wheelchair, Diana,s family cannot haul the wheelchair.  So if ... the car, and Diana is left to wait for ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology: